CN113825514A - 阿比特龙-环状寡聚体药物制剂及其形成和施用方法 - Google Patents

阿比特龙-环状寡聚体药物制剂及其形成和施用方法 Download PDF

Info

Publication number
CN113825514A
CN113825514A CN202080036072.5A CN202080036072A CN113825514A CN 113825514 A CN113825514 A CN 113825514A CN 202080036072 A CN202080036072 A CN 202080036072A CN 113825514 A CN113825514 A CN 113825514A
Authority
CN
China
Prior art keywords
abiraterone
pharmaceutical formulation
patient
crystalline
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080036072.5A
Other languages
English (en)
Chinese (zh)
Inventor
达夫·米勒
乌尔维·加拉
罗伯特·O·威廉斯三世
安杰拉·斯潘根贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Austinpx LLC
Original Assignee
University of Texas System
DisperSol Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, DisperSol Technologies LLC filed Critical University of Texas System
Publication of CN113825514A publication Critical patent/CN113825514A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080036072.5A 2019-03-18 2020-03-17 阿比特龙-环状寡聚体药物制剂及其形成和施用方法 Pending CN113825514A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820076P 2019-03-18 2019-03-18
US62/820,076 2019-03-18
US201962942111P 2019-11-30 2019-11-30
US62/942,111 2019-11-30
PCT/US2020/023066 WO2020190900A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Publications (1)

Publication Number Publication Date
CN113825514A true CN113825514A (zh) 2021-12-21

Family

ID=72521270

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080036072.5A Pending CN113825514A (zh) 2019-03-18 2020-03-17 阿比特龙-环状寡聚体药物制剂及其形成和施用方法

Country Status (9)

Country Link
US (1) US20220362264A1 (https=)
EP (1) EP3941478A4 (https=)
JP (1) JP2022525425A (https=)
CN (1) CN113825514A (https=)
AU (1) AU2020240017A1 (https=)
BR (1) BR112021018540A2 (https=)
CA (1) CA3133620A1 (https=)
IL (1) IL286416A (https=)
WO (1) WO2020190900A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
CN107205935A (zh) * 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107205935A (zh) * 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
潘卫三: "《药用高分子材料学》", 中国医药科技出版社, pages: 361 - 364 *

Also Published As

Publication number Publication date
AU2020240017A1 (en) 2021-11-04
US20220362264A1 (en) 2022-11-17
BR112021018540A2 (pt) 2021-11-30
WO2020190900A1 (en) 2020-09-24
EP3941478A1 (en) 2022-01-26
JP2022525425A (ja) 2022-05-13
IL286416A (en) 2021-10-31
EP3941478A4 (en) 2022-12-28
WO2020190900A8 (en) 2021-10-14
CA3133620A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP2023182674A (ja) アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法
JP6697473B2 (ja) 酢酸アビラテロンの複合体、その製造のための方法、およびそれらを含有する医薬組成物
Kalia et al. Solid dispersions: an approach towards enhancing dissolution rate
EP2575785B1 (en) Oral dosage forms of bendamustine and therapeutic use thereof
Kumar et al. Guargum and Eudragit® coated curcumin liquid solid tablets for colon specific drug delivery
JP2010525082A (ja) 固体投与形
KR20030041577A (ko) 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
TWI285116B (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
CN107735092A (zh) 可用于治疗急性疼痛的美洛昔康‑环糊精包合物及制备方法
KR20200118117A (ko) 소아용 니라파립 제제 및 소아용 치료 방법
CN106265580A (zh) Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
Conceição et al. Orodispersible carbamazepine/hydroxypropyl-β-cyclodextrin tablets obtained by direct compression with five-in-one co-processed excipients
Narala et al. Preparation and in vitro evaluation of hot-melt extruded pectin-based pellets containing ketoprofen for colon targeting
WO2015032873A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
US20220401579A1 (en) Inclusion complexes of pharmaceuticals and cyclic oligomers
CN113825514A (zh) 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
CN121818963A (zh) 维拉佐酮包合物及其组合物和制备方法
WO2023078265A1 (zh) 一种固体分散体、其制备方法及包含其的固体制剂
CN118302165A (zh) 维拉佐酮组合物及其药物制剂、制备方法和用途
Thompson et al. Can the oral bioavailability of the discontinued prostate cancer drug galeterone Be improved by processing method? KinetiSol® outperforms spray drying in a head-to-head comparison
CN101094656A (zh) 含低剂量雌二醇的口服固体剂型
Choudhari et al. Engineering Amorphous Solid Dispersions of Abiraterone Acetate via HPMC HME: A Polymer-Centric Hot-Melt Extrusion Strategy for Formulation-Driven Bioavailability Improvement.
EP3041462A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Texas, USA

Applicant after: Austin Pharmaceutical Co.,Ltd.

Applicant after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Address before: Texas, USA

Applicant before: DISPERSOL TECHNOLOGIES, LLC

Applicant before: BOARD OF REGENTS THE University OF TEXAS SYSTEM

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211221

WD01 Invention patent application deemed withdrawn after publication